Buprenorphine and Lumacaftor: Interaction Details
AI-assisted, pharmacist-reviewed · AI content regenerated Jul 11, 2026 · Source data updated Jul 2, 2026 · Sources: FDA labeling, DDInter 2.0, cited literature
Buprenorphine
Lumacaftor
No brand names on record
How we grade severity & evidence
Severity levels
- Contraindicated: These should generally not be used together.
- Major: Potentially serious — often needs a change or close monitoring.
- Moderate: Can be significant — usually manageable with monitoring.
- Minor: Usually limited clinical impact.
Evidence grades
- Established: Well documented — supported by controlled studies or strong clinical data.
- Probable: Good supporting evidence, though not definitively proven.
- Suspected: Some evidence suggests this interaction, but it is not well established.
- Possible: Limited or conflicting evidence; the interaction may occur.
- Theoretical: Predicted from the drugs' pharmacology; not yet confirmed in people.
Ratings come from the documented interaction literature and are reviewed by a pharmacist. They describe the documented risk of the combination, not what will necessarily happen to you — your dose, timing, and health picture all matter.
Let me explain how these two work together. Lumacaftor speeds up the enzyme (called CYP3A4) that breaks down buprenorphine. That means your body clears buprenorphine faster, so there is less of it in your blood. The result can be a weaker effect from your buprenorphine, and you might notice opioid withdrawal symptoms like chills, sweating, achiness, stomach upset, or feeling restless.
The good news is your care team can manage this smoothly. They may adjust your buprenorphine dose and watch how you are doing. Please keep taking both medicines as prescribed, and reach out to your pharmacist or doctor if you start feeling any withdrawal symptoms so they can help.
Effect: Reduced buprenorphine exposure and efficacy via lumacaftor-mediated induction of CYP3A4, increasing buprenorphine metabolism. Direction is decreased plasma buprenorphine (neither agent is activated by this pathway).
- Risk: Opioid withdrawal; inadequate analgesia or destabilized maintenance therapy.
- Severity/evidence: Major; probable. Onset unspecified.
- Management: If the inducer is necessary, titrate buprenorphine upward until stable effect and monitor for withdrawal. On inducer discontinuation, consider dose reduction and monitor for respiratory depression. For long-acting subQ formulations, verify adequate levels; if precise titration is needed, use a transmucosal formulation.
What happens
Reduced buprenorphine exposure and reduced efficacy of buprenorphine
Interaction Deep Dive
Taking buprenorphine together with a CYP3A4 inducer can produce opioid withdrawal symptoms, because the inducer lowers buprenorphine plasma levels. Should a patient on buprenorphine require a CYP3A4 inducer, one option is to raise the buprenorphine dose until stable drug effects are reached, while watching for signs of withdrawal. Conversely, when a CYP3A4 inducer is stopped in someone maintained on buprenorphine, consider lowering the buprenorphine dose and observe for respiratory depression2. In cases where dosing cannot be modified after the CYP3A4 inducer is removed, switch the patient back to a buprenorphine formulation that allows finer dose titration. For patients being converted from transmucosal buprenorphine given alongside CYP3A4 inducers, verify that the buprenorphine plasma level achieved with subQ buprenorphine is sufficient. When a patient already receiving subQ buprenorphine needs a CYP3A4 inducer, monitor for withdrawal. If the buprenorphine dose proves inadequate while the concomitant drug is present, and that drug cannot be decreased or stopped, then adjust the buprenorphine dose. Where the available doses cannot deliver the target dose, treat the patient with a buprenorphine formulation that permits more precise dose adjustments 1.
Why it happens (mechanism)
Induction of CYP3A4-mediated metabolism of buprenorphine
How to manage this interaction
This is manageable with the right adjustments and monitoring. Here is what typically happens:
- Keep taking both medications exactly as prescribed unless your care team tells you otherwise.
- Because lumacaftor can lower your buprenorphine levels, your team may adjust and individualize your buprenorphine dose and monitor you more closely for withdrawal.
- If lumacaftor is later stopped, your team may lower your buprenorphine dose and watch for over-sedation or slowed breathing.
- Tell your pharmacist or prescriber promptly if you feel withdrawal symptoms (chills, sweating, cramps, restlessness) or, if lumacaftor stops, unusual drowsiness.
Management is individual — confirm any change with your pharmacist or prescriber.
Literature reports
1 report — tap to read
a) The impact of a concurrently administered CYP3A4 inducer on buprenorphine exposure in patients receiving subQ buprenorphine has not been investigated; nevertheless, interactions of this kind have been demonstrated in studies employing transmucosal buprenorphine. The effects of buprenorphine may vary according to the route of administration 1.
Common questions
Can I take Buprenorphine and Lumacaftor together?
Lumacaftor can speed up the breakdown of buprenorphine, lowering its levels and possibly triggering withdrawal or reduced pain control. Keep taking both as prescribed and tell your care team about any withdrawal symptoms so they can adjust your dose and monitor you. Always confirm with your pharmacist or prescriber before making any change.
How serious is the Buprenorphine and Lumacaftor interaction?
It is rated major. Potentially serious — often needs a change or close monitoring.
How quickly could this interaction happen?
The documented onset is "unspecified". The timing of this interaction is not well characterized.
How is the Buprenorphine and Lumacaftor interaction managed?
This is manageable with the right adjustments and monitoring. Here is what typically happens: Keep taking both medications exactly as prescribed unless your care team tells you otherwise. Because lumacaftor can lower your buprenorphine levels, your team may adjust and individualize your buprenorphine dose and monitor you more closely for withdrawal. If lumacaftor is later stopped, your team may lo… Management is individual — always follow your own care team's guidance.
How strong is the evidence for this interaction?
The evidence is graded "probable". Good supporting evidence, though not definitively proven.
Questions for your pharmacist
- Does my dose of Buprenorphine or Lumacaftor need adjusting while I take them together?
- What symptoms should prompt me to call you or my prescriber right away?
- Does the timing of my doses matter for this combination?
- Is there a safer alternative to one of these medications for me?
References (2)
- Product Information: BRIXADI(TM) subcutaneous extended-release injection, buprenorphine subcutaneous extended-release injection. Braeburn Inc (per FDA), Plymouth Meeting, PA, 2023. DailyMed
- Product Information: ZUBSOLV(R) sublingual tablets, buprenorphine naloxone sublingual tablets. Orexo US Inc (per FDA), Morristown, NJ, 2023. DailyMed
Keep reading about Buprenorphine
Keep reading about Lumacaftor
These medications also interact with supplements
Prescription drugs aren't the whole picture — herbal and dietary supplements can interact with them too. From the evidence-graded Natural Medicines database:
major · moderate · minor — check everything you take with our drug–supplement interaction checker.
Check another combination
Our instant two-drug interaction checker is almost here.
Still have questions about this combination?
Every question gets a real answer from a licensed pharmacist — free, and usually within a day.
Ask the pharmacist